IS7136A - Aðferð til meðhöndlunar á svefnleysi á frumstigi - Google Patents

Aðferð til meðhöndlunar á svefnleysi á frumstigi

Info

Publication number
IS7136A
IS7136A IS7136A IS7136A IS7136A IS 7136 A IS7136 A IS 7136A IS 7136 A IS7136 A IS 7136A IS 7136 A IS7136 A IS 7136A IS 7136 A IS7136 A IS 7136A
Authority
IS
Iceland
Prior art keywords
treatment
early insomnia
insomnia
early
Prior art date
Application number
IS7136A
Other languages
English (en)
Other versions
IS3004B (is
Inventor
Zisapel Nava
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7136(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of IS7136A publication Critical patent/IS7136A/is
Publication of IS3004B publication Critical patent/IS3004B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
IS7136A 2001-08-14 2002-08-12 Aðferð til meðhöndlunar á svefnleysi á frumstigi IS3004B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL144900A IL144900A (en) 2001-08-14 2001-08-14 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
PCT/IL2002/000662 WO2003015690A2 (en) 2001-08-14 2002-08-12 Method for treating primary insomnia

Publications (2)

Publication Number Publication Date
IS7136A true IS7136A (is) 2004-01-30
IS3004B IS3004B (is) 2018-09-15

Family

ID=11075696

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7136A IS3004B (is) 2001-08-14 2002-08-12 Aðferð til meðhöndlunar á svefnleysi á frumstigi

Country Status (35)

Country Link
US (1) US8962024B2 (is)
EP (2) EP1441702B1 (is)
JP (1) JP2005501095A (is)
KR (1) KR20040032917A (is)
CN (1) CN100453078C (is)
AR (1) AR034975A1 (is)
AU (1) AU2002326114C1 (is)
BR (1) BR0211855A (is)
CA (1) CA2454699C (is)
CL (1) CL2002001701A1 (is)
CR (1) CR7271A (is)
CY (2) CY1118924T1 (is)
DK (2) DK1441702T3 (is)
EA (1) EA200400302A1 (is)
ES (2) ES2626591T3 (is)
GT (1) GT200200164A (is)
HU (1) HU230786B1 (is)
IL (1) IL144900A (is)
IS (1) IS3004B (is)
JO (1) JO3446B1 (is)
LT (1) LT1441702T (is)
MX (1) MXPA04001372A (is)
NO (1) NO334788B1 (is)
NZ (1) NZ531318A (is)
PA (1) PA8552301A1 (is)
PE (1) PE20030331A1 (is)
PL (1) PL367872A1 (is)
PT (2) PT3103443T (is)
PY (1) PY0218122A (is)
RU (1) RU2560840C2 (is)
SI (1) SI1441702T1 (is)
UA (1) UA87262C2 (is)
UY (1) UY27401A1 (is)
WO (1) WO2003015690A2 (is)
ZA (1) ZA200402005B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008116004A2 (en) 2007-03-19 2008-09-25 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
DK3337462T3 (da) 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378109B (is) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (is) 1972-05-19 1975-08-18 Bofors Ab
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (en) 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707652A (en) 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
DE69229490T2 (de) 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0565296T3 (da) * 1992-04-07 1996-12-09 Neurim Pharma 1991 Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IL103411A (en) 1992-10-11 1996-11-14 Neurim Pharma 1991 Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
DK0674624T3 (da) 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
BR9307646A (pt) 1992-12-17 1999-05-25 Pfizer Pirrolopirimidinas como antagonistas de crf
KR100190730B1 (ko) 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
WO1995003043A1 (en) 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5654325A (en) 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) * 1995-10-03 1998-05-22 Interneuron Pharma Blandinger av melatonin og analgetika samt anvendelser derav
EP0912174B1 (en) * 1996-07-17 2004-04-28 MERCK & CO., INC. Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5826408A (en) * 1997-05-08 1998-10-27 Riverwood International Corporation Rotary flap tucker for a cartoning machine
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
IL150190A0 (en) * 2000-01-05 2002-12-01 Neurim Pharma 1991 Method and formulation for treating resistance to antihypertensives and related conditions
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6703412B1 (en) 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
CA2850162A1 (en) 2011-09-27 2013-04-04 IBIS Medical, Inc. Intragastric implant devices

Also Published As

Publication number Publication date
WO2003015690A2 (en) 2003-02-27
EP1441702B1 (en) 2017-05-10
GT200200164A (es) 2003-09-26
HUP0401042A2 (hu) 2004-08-30
IS3004B (is) 2018-09-15
PY0218122A (es) 2004-03-01
NZ531318A (en) 2005-08-26
AU2002326114B2 (en) 2007-03-08
BR0211855A (pt) 2004-09-21
PT3103443T (pt) 2021-08-12
AR034975A1 (es) 2004-03-24
HUP0401042A3 (en) 2009-07-28
LT1441702T (lt) 2017-06-12
CY1118924T1 (el) 2018-01-10
EP1441702A2 (en) 2004-08-04
AU2002326114A1 (en) 2003-03-03
HK1066161A1 (zh) 2005-03-18
EA200400302A1 (ru) 2004-10-28
WO2003015690B1 (en) 2004-03-11
CN100453078C (zh) 2009-01-21
ES2882584T3 (es) 2021-12-02
PL367872A1 (en) 2005-03-07
PE20030331A1 (es) 2003-06-27
EP1441702A4 (en) 2007-09-26
CR7271A (es) 2004-05-17
UY27401A1 (es) 2003-02-28
US8962024B2 (en) 2015-02-24
MXPA04001372A (es) 2005-06-06
IL144900A (en) 2013-12-31
PT1441702T (pt) 2017-06-02
ES2626591T3 (es) 2017-07-25
IL144900A0 (en) 2002-06-30
CN1541092A (zh) 2004-10-27
ZA200402005B (en) 2005-07-27
DK3103443T3 (da) 2021-08-30
PA8552301A1 (es) 2003-06-30
CY1124763T1 (el) 2022-07-22
SI1441702T1 (sl) 2017-08-31
CA2454699A1 (en) 2003-02-27
EP3103443B1 (en) 2021-06-30
JP2005501095A (ja) 2005-01-13
US20040248966A1 (en) 2004-12-09
NO334788B2 (no) 2014-05-26
AU2002326114C1 (en) 2019-03-21
NO20040087L (no) 2004-02-19
KR20040032917A (ko) 2004-04-17
WO2003015690A3 (en) 2003-09-25
NO334788B1 (no) 2014-05-26
JO3446B1 (ar) 2020-07-05
HU230786B1 (en) 2018-05-02
RU2011131532A (ru) 2013-03-27
EP3103443A1 (en) 2016-12-14
DK1441702T3 (en) 2017-06-06
CL2002001701A1 (es) 2010-06-25
RU2560840C2 (ru) 2015-08-20
CA2454699C (en) 2012-03-27
UA87262C2 (uk) 2009-07-10

Similar Documents

Publication Publication Date Title
NO20035156L (no) Fremgangsmåter for brønnbehandling
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
NO20035610L (no) Fremgangsmate for behandling av vaeskeformig hydrokarbon
IS6785A (is) EP4 viðtakahindrar til meðhöndlunar á liðagigt
EP1446129A4 (en) POLYNUCLEOTIDE THERAPY
DE60217317T8 (de) Wärmebehandlungsverfahren
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
IS2223B (is) Aðferð til framleiðslu á 5-sýanóþalíði
NO20040353L (no) Ny terapeutsk metode
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
NO20045554L (no) Fremgangsmate for behandling av diabetes
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
IS3004B (is) Aðferð til meðhöndlunar á svefnleysi á frumstigi
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
DE60219903D1 (de) Wärmebehandlungseinrichtung
DE60226093D1 (de) Urmedium-Reinigungsmethode
IS6992A (is) Meðhöndlun á ADHD
FI20011954L (fi) Lämpökäsittelymenetelmä